EMA Proposes Revisions to Module V of GVPs on Risk Management Systems

The European Medicines Agency has begun a public consultation on planned revisions to Module V of the good pharmacovigilance practices on risk management systems, which clarifies what risk management plans to focus on over a product’s lifecycle.
Source: International Pharmaceutical Regulatory Monitor